ARATANA THERAPEUTICS, INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014
Assets
Current assets:
Cash and cash equivalents
Short-term marketable securities
Short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Deferred tax asset
Total current assets

Property and equipment, net
Long-term marketable securities
Operating lease right-of-use asset
Goodwill
Intangible assets, net
Restricted cash
Other long-term assets
Total assets

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses
Current portion-contingent consideration
Deferred income
Deferred tax liability
Accrued expenses and other current liabilities
Licensing and collaboration commitment
Current portion – loans payable
Current portion-deferred licensing revenue
Other current liabilities
Current portion – operating lease liability
Total current liabilities

Loans payable, net
Deferred tax liability
Operating lease liability
Other long-term liabilities
Total liabilities
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2019 and December 31, 2018 and 48,347,297 and 48,048,914 issued and outstanding at March 31, 2019 and December 31, 2018, respectively
Treasury stock, at cost; 129,603 and 94,107 shares at March 31, 2019 and December 31, 2018, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders' equity
Total liabilities and stockholders' equity

Comments